ADC

Highlights from landmark November studies in thoracic oncology.

Highlights from landmark October studies in thoracic oncology.

The most practice-changing, promising, and watchlist data — distilled into 3 bullets each.

ESMO 2025 brings a strong thoracic-oncology program, spanning peri-operative immunotherapy, next-generation ADCs, and long-term targeted-therapy follow-up. Below are ten key abstracts to keep on your radar.

Ten lung cancer studies to have on your radar across ADCs, peri-op immunotherapy, EGFR with brain mets, and KRAS G12C combos — plus three embargoed heavy-hitters to unveil during plenaries.